Published: Friday, February 28, 2025 · 12:37 PM | Updated: Friday, February 28, 2025 · 12:37 PM
📊 321 views
🗝️ Key Points
- On February 28, 2025, Fulgent Genetics Inc (FLGT, Financial) released its 8-K filing detailing the financial results for the fourth quarter and full year ending December 31, 2024.
- Fulgent Genetics Inc, a technology company specializing in genetic testing and therapeutic development, reported a total revenue of $76.2 million for Q4 2024, slightly.
- The company's laboratory services business, which includes technical laboratory services and professional interpretation of results, is a significant revenue driver.
On February 28, 2025, Fulgent Genetics Inc (FLGT, Financial) released its 8-K filing detailing the financial results for the fourth quarter and full year ending December 31, 2024. Fulgent Genetics Inc, a technology company specializing in genetic testing and therapeutic development, reported a total revenue of $76.2 million for Q4 2024, slightly surpassing the analyst estimate of $76.09 million. However, the company reported a GAAP loss of $5.9 million, or ($0.19) per share, which was better than the estimated loss of ($0.46) per share.
Company Overview
Fulgent Genetics Inc operates in the medical diagnostics and research industry, focusing on providing genetic testing services and developing therapeutic solutions for cancer treatment. The company’s laboratory services business, which includes technical laboratory services and professional interpretation of results, is a significant revenue driver. The therapeutic development segment is advancing drug candidates for various cancers, with a strong presence in the United States.
Performance and Challenges
Fulgent Genetics Inc’s Q4 2024 performance highlighted a 14% year-over-year growth in core revenue, reaching $76.0 million. Despite this growth, the company faced a GAAP loss, reflecting ongoing challenges in managing costs and investments in research and development. The full-year GAAP loss was $42.7 million, or ($1.41) per share, compared to the annual estimate of ($1.69) per share. These challenges underscore the importance of balancing growth initiatives with financial sustainability.
Financial Achievements
For the full year 2024, Fulgent Genetics Inc reported total revenue of $283.5 million, slightly above the annual estimate of $283.37 million. The company ended the year with a robust cash position of $828.6 million, including cash equivalents, Restricted cash, and investments in marketable securities. This strong cash reserve is crucial for supporting ongoing research and development efforts and potential strategic investments.
Key Financial Metrics
The company’s financial statements reveal important metrics that value investors should consider:
| Metric | Q4 2024 | Full Year 2024 |
|---|---|---|
| Total Revenue | $76.2 million | $283.5 million |
| GAAP Loss | ($5.9 million) | ($42.7 million) |
| Non-GAAP Income | $1.2 million | $15.0 million |
| Cash from Operations | $25.0 million | $21.1 million |
Analysis and Commentary
Fulgent Genetics Inc’s financial results reflect a mixed performance, with revenue growth offset by challenges in profitability. The company’s focus on expanding its laboratory services and advancing its therapeutic pipeline is evident, as highlighted by CEO Ming Hsieh:
I am pleased with the progress of our business in 2024. Laboratory Services exhibited strong growth for the year.”
CFO Paul Kim added,
We are pleased with our financial performance in 2024 and believe we have entered 2025 in a position of strength.”
Looking ahead, Fulgent Genetics Inc projects core revenue of approximately $310 million for 2025, indicating continued growth in its core business. However, the company anticipates a GAAP loss of approximately ($1.95) per share, suggesting ongoing challenges in achieving profitability. Investors will be keen to monitor how the company navigates these challenges while leveraging its strong cash position to drive future growth.
Explore the complete 8-K earnings release (here) from Fulgent Genetics Inc for further details.
MORE IN INSIDE Investment NEWS
The S&P 500 and Nasdaq kept their record rallies going. Here are 3 key takeaways
Published: Saturday, May 2, 2026 · 3:13 PM
Apple’s stock gains as company execs cite iPhone, Mac demand in boosting guidance
Published: Friday, May 1, 2026 · 8:11 PM
